Who
Michael Alfieri
Principal Financial Officer
Company insider
Files Form 4 as: Principal Financial Officer, Aldeyra Therapeutics; Principle Financial Officer, Genocea Biosciences.
In numbers
- Trades disclosed
- 5
- Buys
- 3
- Sells
- 0
- Bought
- $33K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 13 Sep 2018
- Last trade
- 18 Mar 2026
- Last filed
- 19 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Mar 2026filed 19 Mar 2026 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,1005,000 at $1.42 | filing |
| 18 Mar 2026filed 19 Mar 2026 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,1005,000 at $1.42 | filing |
| 13 Aug 2025filed 15 Aug 2025 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Bought | $13K2,500 at $5.30 | filing |
| 7 Feb 2019filed 11 Feb 2019 | Genocea Biosciencesoption or derivative | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 13 Sep 2018filed 14 Sep 2018 | Genocea Biosciences | SEC FORM 4 Bought | $5,40010,000 at $0.54 | filing |
News
No headline names them, or the companies they trade most, lately.